


RealRate

PHARMACEUTICAL 2021

NightHawk Biosciences Inc. Rank 98 of 409









PHARMACEUTICAL 2021





NightHawk Biosciences Inc. Rank 98 of 409

The relative strengths and weaknesses of NightHawk Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NightHawk Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 173% points. The greatest weakness of NightHawk Biosciences Inc. is the variable Revenues, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 31%, being 385% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	113,794
Cost of Goods Sold	0
Intangible Assets	7,318
Liabilities, Current	3,657
Liabilities, Non-Current	1,575
Other Assets	2,406
Other Compr. Net Income	177
Other Expenses	1,199
Other Liabilities	3,468
Other Net Income	-257
Property and Equipment	676
Research and Development	12,939
Revenues	2,948
Selling, General and Administrative Expense	14,934

Output Variable	Value in 1000 USD
Assets	124,195
Liabilities	8,701
Expenses	29,072
Stockholders Equity	115,494
Net Income	-26,381
Comprehensive Net Income	-26,293
Economic Capital Ratio	31%

